Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.35 CAD
Change Today 0.00 / 0.00%
Volume 0.0
AEZ On Other Exchanges
As of 3:59 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

aeterna zentaris inc (AEZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - C$1.68
52 Week Low
05/27/15 - C$0.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AETERNA ZENTARIS INC (AEZ)

Related News

No related news articles were found.

aeterna zentaris inc (AEZ) Related Businessweek News

No Related Businessweek News Found

aeterna zentaris inc (AEZ) Details

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company’s product pipeline includes MACRILEN, which completed the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Quebec City, Canada.

56 Employees
Last Reported Date: 03/17/15
Founded in 1991

aeterna zentaris inc (AEZ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $475.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $309.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Chief Scientific Officer, Chief Medical Offic...
Total Annual Compensation: $265.8K
Vice President of Finance
Total Annual Compensation: $240.0K
Compensation as of Fiscal Year 2014.

aeterna zentaris inc (AEZ) Key Developments

Aeterna Zentaris Inc. Announces Amendments to the Articles

Aeterna Zentaris Inc. at its AGM held on May 8, 2015, approved the filing of articles of amendment to consolidate the issued and outstanding common shares of the corporation.

Aeterna Zentaris Inc. Elects Gérard Limoges as Director

Aeterna Zentaris Inc. elected Gérard Limoges as director at its 2015 shareholders' meeting on May 8, 2015.

Aeterna Zentaris Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Aeterna Zentaris Inc. announced consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $9,536,000 against $8,195,000 a year ago. Net loss from continuing operations was $9,636,000 or $0.13 per basic and diluted share against $4,304,000 or $0.08 per basic and diluted share a year ago. Net income was $9,736,000 or $0.13 per basic and diluted share against $4,356,000 or $0.08 per basic and diluted share a year ago. This increase in net loss is due largely to higher comparative SG&A expenses and to higher comparative net finance costs, partially offset by lower comparative R&D costs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEZ:CN C$0.35 CAD 0.00

AEZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEZ.
View Industry Companies

Industry Analysis


Industry Average

Valuation AEZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 253.8x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETERNA ZENTARIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at